ArticleCardiovascular and interventional radiology2025
A Retrospective, Multicentric Evaluation of the Safety and Efficacy of Transcatheter Arterial Micro Embolization for Refractory Achilles Tendinopathy.
Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transarterial Microembolization in Tendinopathies: From Experimental to Evidence-Based Therapy.Cardiovascular and interventional radiology · 2025Article
- We Saved the Best for Last….Cardiovascular and interventional radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the short- to mid-term outcomes of transcatheter arterial microembolization (TAME) as a therapeutic intervention for pain and disability associated with chronic Achilles tendonitis (AT) refractory to conservative treatment. MATERIALS AND
methodsThis multicenter retrospective study included 82 patients (67 men and 15 women) who underwent TAMEs using imipenem/cilastatin sodium for refractory chronic AT between May 2019 and February 2023. The mean age was 47.3 ± 12.7 years. A Numerical Rating Scale (NRS, 0-10) was used to assess pain at baseline and 1, 2, 3, 6, 12, and 24 months. Clinical success was defined as a decrease of > 50% in the NRS score at 12 months compared with baseline. The Victorian Institute of Sports Assessment (VISA-A) score was used to evaluate pain and function at baseline and 6 and 24 months.
resultsClinical success was achieved in 67 (81.7%) of the 82 patients. The baseline mean NRS was 6.7 ± 1.5, which improved to 4.2 ± 2.0, 3.3 ± 2.0, 2.8 ± 2.2, 2.3 ± 2.2, 1.8 ± 2.2, and 1.5 ± 2.2 at 1, 2, 3, 6, 12, and 24 months, respectively (all p < 0.001). The mean baseline VISA-A score was 48.4 ± 19.1, which improved to 76.9 ± 17.4 and 82.2 ± 17.0 at 6 and 24 months, respectively (all p < 0.001). No major complications or tendon ruptures were observed during the 2 year follow-up period.
conclusionTAME for chronic AT is a safe and effective treatment that improves long-term functional outcomes and can be offered to patients resistant to conservative management.
Indexed as
Identifiers
40775103What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.